The major concern about a powerful new gene-editing technique that most people don't want to talk about
By Tanya Lewis,
Business Insider
| 12. 02. 2015
Scientists, bioethicists, and members of the public have descended on Washington, DC this week for an international meeting to discuss the ethics of a promising lab technique that lets scientists edit our genes.
The technique, known as CRISPR/Cas9, lets scientists cut-and-paste DNA inside cells to correct genetic defects or, potentially, add new capabilities. It offers enormous promise to improve our understanding of biology and to treat or even eliminate genetic diseases.
But there's a dark side to manipulating our genetics that few want to discuss: Eugenics, the racist practice of trying to "improve" the human race by controlling genetics and reproduction.
A disturbingly widespread practice
While eugenics is most commonly associated with Nazi Germany, it was alive and well in the US and in other countries well before World War II, Daniel Kevles, a historian of science at New York University, said during a talk at the gene editing summit on Tuesday.
"Eugenics was not unique to the Nazis. It could — and did — happen everywhere," Kevles said.
He and others worry that gene editing tools like CRISPR...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...